MedTrace Logo

Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease

NCT07262476 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 258

Last updated 2026-03-30

No results posted yet for this study

Summary

This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.

Conditions

  • Thyroid Eye Disease (TED)

Interventions

DRUG

MHB018A injection

MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)

Sponsors & Collaborators

  • Minghui Pharmaceutical (Hangzhou) Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-09
Primary Completion
2029-01-31
Completion
2030-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07262476 on ClinicalTrials.gov